NGM BIOPHARMACEUTICALS INC (NGM)
US62921N1054 - Common Stock
NGM Bio Announces Closing of Tender Offer
NGM Bio Announces Closing of Tender Offer
SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (“NGM Bio”) (Nasdaq: NGM), a biotechnology company focused on discovering...
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CTLT, HRT, NGM, SDPI
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on...
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FREE, HRT, NGM, KNTE
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates EGLE, X, PGTI, NGM
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
--Enrollment ongoing for patients with microsatellite stability (MSS) colorectal cancer (CRC) in Phase1/2 trial of NGM707, a dual ILT2/ILT4 antagonist...
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates EVRI, MDC, NGM, JNPR
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates NGM, AA, HRT, KNTE
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Shareholder Alert: Ademi LLP investigates whether NGM Biopharmaceuticals, Inc. has obtained a Fair Price in its transaction with Atlas Neon
/PRNewswire/ -- Ademi LLP is investigating NGM Bio (Nasdaq: NGM) for possible breaches of fiduciary duty and other violations of law in its transaction with...
NGM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NGM Biopharmaceuticals, Inc. Is Fair to Shareholders
NGM Bio to go private in a $135M deal with Atlas Neon (NASDAQ:NGM)
Biopharmaceutical company NGM Bio is set to be acquired by Atlas Neon, with a merger agreement valuing NGM at $135 million in cash per share.
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP
NGM Bio stockholders to receive $1.55 per share in cash, an 80% premium over the closing share price on the last trading day prior to disclosure of receipt...
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering...
NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering...
NGM Biopharma stock on data for cancer therapy (NASDAQ:NGM)
NGM Biopharmaceuticals (NGM) stock gains as updated data from its ongoing Phase 1/2 trial for cancer therapy showed four partial remissions. Read more here.
NGM Biopharma stock jumps on take-private offer (NASDAQ:NGM)
Shares of NGM Biopharmaceuticals (NGM) rise as venture capital firm The Column Group offers to acquire the company in a take-private deal. Read more here.
Tuesday Sector Leaders: Drugs, Biotechnology Stocks
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®
--As previously reported, the ALPINE 4 study met its primary endpoint, with aldafermin 3 mg demonstrating a statistically significant reduction in Enhanced...